HURA - TuHURA Biosciences, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.65 0.08 (4.85%)	---	0.02 (1.18%)	0.07 (4.22%)	0.0 (0.0%)	0.13 (8.12%)	0.0 (0.0%)	0.03 (1.85%)

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Market